Algoclinic
ActiveSummary
Algoclinic has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3,101 and a net result of €2,101. Its solvency ranks better than 20% of 20,604 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Financials · financial year 2025, micro format
Turnover and EBIT margin not published: the micro format does not require them.
Peer companies
Historical observationOf the 7,976 companies that looked in July 2024 the way this one looks now, 3.6% went bankrupt within 24 months and 94.3% are still going.
- Micro
- 2 to 5 years old
- solvency 10 to 30%
- a profit of 5% of the balance sheet or more
A further 0.3% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: < 0.1% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,475 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 7,976 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2025 |
|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1,652 |
| Gross operating margin9900 | €6,509 |
| Operating profit (loss)9901 | €4,856 |
| Financial charges65/66B | €861 |
| Recurring financial charges65 | €861 |
| Profit (loss) for the period before taxes9903 | €3,996 |
| Income taxes67/77 | €1,895 |
| Profit (loss) for the period9904 | €2,101 |
| Profit (loss) for the period to be appropriated9905 | €2,101 |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €15,756 | |
| Fixed assets21/28 | €821 | |
| Tangible fixed assets22/27 | €821 | |
| Plant, machinery and equipment23 | €821 | |
| Current assets29/58 | €14,935 | |
| Cash at bank and in hand54/58 | €6,468 | |
| Deferred charges and accrued income490/1 | €8,467 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €15,756 | |
| Equity10/15 | €3,101 | |
| Contributions10/11 | €1,000 | |
| Reserves13 | €2,101 | |
| Distributable reserves133 | €2,101 | |
| Amounts payable17/49 | €12,656 | |
| Amounts payable within one year42/48 | €11,986 | |
| Trade debts44 | €2,602 | |
| Suppliers440/4 | €2,602 | |
| Taxes, remuneration and social security45 | €2,925 | |
| Taxes450/3 | €2,925 | |
| Other amounts payable47/48 | €6,459 | |
| Accrued charges and deferred income492/3 | €670 | |
| Line | 2025 |
|---|---|
| Profit (loss) for the period9904 | €2,101 |
| + Depreciation and write-downs630 | €1,652 |
| Operating cash flow (approximation) | €3,753 |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (1)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 30-09-2025 | micro format | 29-04-2026 | 2026-00098190 |
Similar companies · same sector, comparable size
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.